Best Tech Companies To Own For 2014

Defense contractor Northrop Grumman (NYSE: NOC  ) came away from Tuesday’s award of 13 new Pentagon contracts as one of the bigger winners, boasting two contract wins, worth a probable $33 million in aggregate.

In the larger of the two awards, Northrop won $19.5 million as a modification to a previously awarded contract to support vehicle and dismount exploitation radars for the U.S. Army. According to the DoD’s announcement, Northrop’s cumulative wins on this contract now exceed $177 million in total face value. Northrop’s Aerospace division also notched a win, as it was awarded a $13.5 million addition to an existing contract that extended by three years its contract to supply the U.S. Navy with (V)4 Electronic Surveillance Enhancement (ESE) kits and technically refreshed ESEs used in the AN/SLQ-32 anti-ship missile system. The AN/SLQ-32, known unofficially as the “Slick 32” system, is designed to alert a warship of an incoming missile strike and is integrated into the ship’s anti-missile “chaff” and other decoy systems. It can be programmed to deploy anti-missile defenses either semi-automatically, or automatically. The DoD says Northrop’s second contract for these systems now has a ceiling value of $43 million.

link

Best Tech Companies To Own For 2014: Iridium Communications Inc(IRDM)

Iridium Communications Inc. provides mobile voice and data communications services through satellites to businesses, the U.S. and foreign governments, non-governmental organizations, and consumers worldwide. It offers post-paid mobile voice and data satellite communications services; prepaid mobile voice satellite communications services; high-speed data services; machine-to-machine services for sending and receiving data from one location to other; and ancillary services, including inbound connections from the public switched telephone networks, SMS, SIM, activation, customer reactivation, and other peripheral services to commercial customers. The company also offers traditional voice, netted voice, data, messaging, and paging services, as well as maintenance services for the DoD?s dedicated gateway; and offers voice and data solutions, including personnel tracking devices; over-the-horizon aircraft communications applications; submarine communications applications; spec ialized communications solutions for high-value individuals; asset tracking devices for equipment, vehicles, and aircraft; and secure mobile communications and data devices for the military and intelligence community, such as secure satellite handsets to U.S. government customers. In addition, it manufactures and sells satellite handsets, voice and data modems, high-speed data devices, and machine-to-machine data devices. Further, the company offers accessories for its devices, including holsters, earbuds, portable auxiliary antennas, antenna adaptors, USB data cables, and charging units. Additionally, it provides engineering and support services to commercial and government customers. The company sells products and services to commercial end-users through service providers, value-added resellers, and value-added manufacturers. As of March 31, 2011, it had approximately 447,000 billable subscribers. The company was founded in 2000 and is headquartered in McLean, Virginia.

Advisors’ Opinion:

  • [By John Udovich]

    Jim Cramer, the host of CNBC’s Mad Money, recently touted ViaSat, Inc (NASDAQ: VSAT) as an in-flight WiFi or satellite communications related play, meaning its worth taking a closer look at the stock along with the performance of small cap in-flight WiFi provider Gogo Inc (NASDAQ: GOGO) and small cap satellite communications firm Iridium Communications Inc (NASDAQ: IRDM). I should mention that I have written about Gogo Inc in the past (Small Cap Gogo Inc (GOGO): Is There Turbulence Ahead? IRDM and Is In-flight WiFi Stock Gogo, Inc. (GOGO) the Next Iridium?) and Cramer also touched on some of the differences between the in-flight wifi service offerings of both. Cramer also interviewed ViaSat, Inc’s CEO who said they had been waiting for a new satellite to “disrupt” the market.

  • [By Jake L’Ecuyer]

    Telecommunications services sector gained 0.12 percent in the US market today. Among the sector stocks,Iridium Communications (NASDAQ: IRDM) was down more than 4.5 percent, while America Movil S.A.B. de C.V. (NYSE: AMX) tumbled around 2.3 percent.

  • [By Jake L’Ecuyer]

    Telecommunications services sector gained 0.12 percent in the US market today. Among the sector stocks, Iridium Communications (NASDAQ: IRDM) was down more than 4.5 percent, while America Movil S.A.B. de C.V. (NYSE: AMX) tumbled around 2.3 percent.

  • [By John Udovich]

    Small cap Gogo Inc (NASDAQ: GOGO) leaped 10.04% yesterday after announcing its first international deal where it would provide in-flight Internet service on the entire domestic fleet of Japan Airlines (JAL) – meaning it might be a good idea to take a closer look at the stock along with Iridium Communications Inc (NASDAQ: IRDM), another formerly highflying communications stock that hit heavy turbulence and ultimately crashed over a decade ago.

Best Tech Companies To Own For 2014: Agilysys Inc.(AGYS)

Agilysys, Inc., together with its subsidiaries, provides information technology (IT) solutions to corporate and public-sector customers primarily in North America. It operates in three segments: Hospitality Solutions Group (HSG), Retail Solutions Group (RSG), and Technology Solutions Group (TSG). The HSG segment offers application software and services that streamline management of operations, property, and inventory for customers in the gaming, hotel and resort, cruise lines, food management services, and sports and entertainment markets. The RSG segment provides solutions for retailers to enhance productivity, operational efficiency, technology utilization, customer satisfaction, and in-store profitability that comprise customized pricing, inventory, and customer relationship management systems. This segment also offers implementation plans and supplies the hardware package required to operate the systems, including servers, receipt printers, point-of-sale terminals, and wireless devices for in-store use by retail store associates. The TSG segment provides various solutions that comprise enterprise architecture, infrastructure optimization, storage and resource management, identity management, and business continuity for the finance, government, healthcare, telecommunications, education, and other industries. The company was founded in 1963 and is headquartered in Solon, Ohio.

Advisors’ Opinion:

  • [By Evan Niu, CFA]

    What: Shares of Agilysys (NASDAQ: AGYS  ) have soared today by as much as 11% after the company reported earnings.

    So what: Revenue in the fiscal fourth quarter rose 21% to $63 million, with the company’s retail segment driving nearly all of those gains. Non-GAAP net income per share came in at $0.15, swinging into the black relative to the $0.16 per share adjusted loss a year ago. CEO James Dennedy said the company outperformed its expectations for the year.

  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Agilysys (Nasdaq: AGYS  ) , whose recent revenue and earnings are plotted below.

Best Tech Companies To Own For 2014: ImmunoCellular Therapeutics Ltd (IMUC)

ImmunoCellular Therapeutics, Ltd., incorporated on March 20, 1987, is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company’s products include ICT-107, ICT-140, ICT-120, ICT-109 and DIAAD. ICT-107, the pipeline product, is a Phase II therapeutic dendritic cell (DC) vaccine for the treatment of glioblastoma multiforme (GBM), the common and lethal type of brain cancer. ICT-107 is designed to activate a patient’s immune system to target six different tumor-associated antigens. In February 2012, it acquired a world-wide license from the University of Pennsylvania and The John Hopkins University (JHU).

The Company in addit ion to ICT-107, is also developing other therapeutic DC vaccines: ICT-140 for ovarian cancer and ICT-121 for recurrent GBM. ICT-140 targets seven tumor-associated antigens expressed on ovarian cancer cells. ICT-107 is a DC vaccine that targets six different tumor-associated antigens that are found on patients’ tumor cells; four of the six antigens are expressed on CSCs. The therapeutic vaccine is used subsequent to conventional therapy or concomitantly with chemotherapy in patients with newly diagnosed GBM. ICT-140 is a DC vaccine that targets seven different ovarian cancer antigens. ICT-121 is a DC vaccine that targets CD133 antigens; it has the potential to be a universal cancer vaccine because CD133 is widely expressed on CSCs from a majority of cancers. Data from this small study demonstrated that ICT-109 had a statistically ability to discriminate between cancerous and non-cancerous samples, suggesting the potential to detect pancreatic and lung cancer in plasma and s erum study sets. The DIAAD (differential immunization for an! tigen and antibody discovery) platform it acquired from Molecular Discoveries utilizes immunological tolerization to accelerate the discovery of the molecular differences between diseased cells and their normal counterparts. The monoclonal antibodies produced by DIAAD provide the basis for the discovery and development of its potential diagnostic and therapeutic products.

The Company competes with Dendreon, Oncothyreon, Galena, Bavarian Nordic and Immunovaccine, Northwest Biotherapeutics, Prima Biomed, DCPrime, Roche/Genentech, Seattle Genetics, Bristol-Myers Squibb and Immunogen.

Advisors’ Opinion:

  • [By Monica Gerson]

    ImmunoCellular Therapeutics (NYSE: IMUC) dropped 11.05% to $1.3699. ImmunoCellular’s trailing-twelve-month ROE is -59.80%.

    Posted-In: market losersNews Movers & Shakers Intraday Update Markets

  • [By Wallace Witkowski]

    Shares of ImmunoCellular (IMUC)  jumped after the drug developer said data on a mid-stage brain cancer drug study were looking encouraging.

  • [By Lauren Pollock]

    ImmunoCellular Therapeutics Ltd.(IMUC) said its leading product candidate, a dendritic cell-based vaccine for brain cancer, didn’t show a statistically significant advantage in overall survival in a Phase II study. In a research note, Maxim Group said it is pushing its EU approval date target to 2019 and lowered its estimate on the stock to $12 a share from $18 a share. The stock plunged 62% to $1.04 premarket.

Best Tech Companies To Own For 2014: MER Telemanagement Solutions Ltd.(MTSL)

Mer Telemanagement Solutions Ltd., together with its subsidiaries, designs, develops, markets, and supports a line of telecommunication expense management (TEM), and customer care and billing solutions for business organizations and other enterprises worldwide. Its TEM solutions assist enterprises and organizations in the allocation of costs, budget control, fraud detection, processing of payments, and spending forecasting. The company also offers converged billing solutions, including applications for charging and invoicing customers, interconnect billing, and partner revenue management through pre-pay and post-pay schemes for wireless providers, voice over Internet protocol, Internet protocol television, and content service providers. Its products provide telecommunication and information technology managers with tools to reduce communication costs, recover charges payable by third parties, and to detect and prevent abuse and misuse of telephone networks comprising fault telecommunication usage. The company markets its products through its direct sales force, distributors, and business telephone switching systems manufacturers and vendors. Mer Telemanagement Solutions Ltd. was founded in 1995 and is headquartered in Raanana, Israel.

Advisors’ Opinion:

  • [By Monica Gerson]

    MER Telemanagement Solutions (NASDAQ: MTSL) dropped 14.62% to $2.09 after the company terminated MVNE solution provider agreement with SBC Communications.

  • [By James E. Brumley]

    Trading can be a quirky game sometimes. Most of the time, news – or at least loudly voiced opinions – tend to result from or be the cause of a fast-moving stock. Every now and then though, as in the case with MER Telemanagement Solutions Ltd. (NASDAQ:MTSL), a stock can build up steam with little to no news linked to that move. That doesn’t make that stock a poor pick, however. Indeed, MTSL looks like it’s turning into a homerun, and that alone is worth a look…. and maybe even worth a shot.

  • [By Bryan Murphy]

    If you’re a small cap enthusiast looking for some budding ideas, you may not need to look any further than China GengSheng Minerals, Inc. (NYSEMKT:CHGS), Bio Matrix Scientific Group Inc. (OTCMKTS:BMSN), and MER Telemanagement Solutions Ltd. (NASDAQ:MTSL). All three have either pushed themselves to the brink of a breakout, if they haven’t started one already. Here’s a closer technical look at MTSL, BMSN, and CHGS, and what it’s going to take to get them going if they’re not going already.

Best Tech Companies To Own For 2014: ARIAD Pharmaceuticals Inc.(ARIA)

ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company?s lead cancer product, ridaforolimus is being studied in multiple clinical trials in patients with various types of cancers, including metastatic sarcomas, breast cancer, endometrial cancer, prostate cancer, and non-small cell lung cancer. Its product pipeline also includes ponatinib, a pan BCR-ABL inhibitor in phase 2 clinical trial for applications in various hematological cancers and solid tumors; and AP26113, an anaplastic lymphoma kinase inhibitor in preclinical studies for the treatment of various cancers, including non-small cell lung cancer, lymphoma, and neuroblastoma. In addition, the company focuses on a drug discovery program centered on small-molecule therapies that are molecularly targeted to cell-signaling pathways implicated in cancer. Further, it licenses its ARGENT cell-sign aling regulation technologies to pharmaceutical and biotechnology companies to develop and commercialize therapeutic products, and to conduct drug discovery research. The company has collaboration and license agreements with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus to prevent restenosis of injured vessels. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is based in Cambridge, Massachusetts.

Advisors’ Opinion:

  • [By Jason Shubnell]

    Ariad Pharmaceuticals (NASDAQ: ARIA) was also up, gaining 7.43 percent to $8.16 on a report from the UK Daily Mail that Jazz Pharmaceuticals is willing to pay $20.00 per share for the maker of Iclusig.

  • [By Bryan Murphy]

    Considering I’m tired of saying it, there’s a good chance you’re tired of hearing it. Yet, if it needs to be said, then it needs to be said – Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is acting like it wants to go higher, and taking that hint in the recent past has paid off well, even if only temporarily.

  • [By Bryan Murphy]

    If you’re frustrated by Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), you’re probably not the only one. The stock’s been maddening to trade since October, stopping in its tracks the minute a trend just seems to start, and then starting a trend out of nowhere (both up and down). Yet, there’s a good case to be made just to buy ARIA and stick with it, and ride out the hot and cold phases as they materialize. Indeed, if history repeats itself, now may be a great time to wade in.

Best Tech Companies To Own For 2014: Apple Inc.(AAPL)

Apple Inc., together with subsidiaries, designs, manufactures, and markets personal computers, mobile communication and media devices, and portable digital music players, as well as sells related software, services, peripherals, networking solutions, and third-party digital content and applications worldwide. The company sells its products worldwide through its online stores, retail stores, direct sales force, third-party wholesalers, resellers, and value-added resellers. In addition, it sells third-party Mac, iPhone, iPad, and iPod compatible products, including application software, printers, storage devices, speakers, headphones, and other accessories and peripherals through its online and retail stores; and digital content and applications through the iTunes Store. The company sells its products to consumer, small and mid-sized business, education, enterprise, government, and creative markets. As of September 25, 2010, it had 317 retail stores, including 233 stores in the United States and 84 stores internationally. The company, formerly known as Apple Computer, Inc., was founded in 1976 and is headquartered in Cupertino, California.

Advisors’ Opinion:

  • [By MONEYMORNING.COM]

    Apple Inc. (Nasdaq: AAPL) is reportedly interested in acquiring Renesas SP Drivers, a Japanese chip maker whose products are designed to improve smartphone image display and preserve battery life.

  • [By MONEYMORNING.COM]

    Icahn is still around. And he’s still active. Only now – in the politically correct 2000s – he’s known as an “activist investor” who’s gone up against the likes of Apple Inc. (Nasdaq: AAPL) and eBay Inc. (Nasdaq: EBAY).

Best Tech Companies To Own For 2014: Dassault Systemes SA (DASTY)

Dassault Systemes SA provides software solutions and consulting services. The Company’s global customer base includes companies primarily in 11 industrial sectors: automotive; industrial equipment; aerospace; consumer goods; consumer packaged goods; energy; high-tech; shipbuilding; life sciences; construction, and business services. It organizes its business and markets its products and services in two types of applications: the Product Lifecycle Management (PLM) market, to support product development, production, maintenance and lifecycle management, and the Mainstream three-dimensional (3D) market, which is primarily focused on product design. Its software applications address a range of products, from apparel, consumer goods, machine parts and semiconductors to automobiles, aircraft, ships and factories. In March 2011, the Company acquired Intercim. In April 2011, the Company acquired Enginuity PLM. On March 31, 2010, it acquired the IBM PLM. On June 8, 2010, the Comp any acquired Exalead, a French company providing Search Platforms and Search-Based Applications (SBA). In June 2010, the Company acquired Geensoft, a provider of embedded systems development solutions.

The Company has developed a software applications portfolio, organized in brands, in order to provide solutions responding to the requirements of product development: Design, Realistic Simulation, Digital Manufacturing and Production, Collaborative Innovation, and Lifelike Experiences. The Company’s principal brands include SolidWorks , CATIA, SIMULIA, DELMIA, ENOVIA and Universal Services.

SolidWorks

SolidWorks applications include 3D tools to design, manage, simulate, sustain and communicate. SolidWorks include 3D Design, Data management, Simulation and Environmental assessments. SolidWorks 3D’s include complex part and assembly modeling, production drawing creation, data management, design validation and simulation of motion, flow and structural performance, environmental impact evaluation! and publishing. SolidWorks Data Management solutions enable control over all design information, eliminating concerns about version control or data loss. SolidWorks simulation technology ensures the quality and performance of the design before users commit to production. SolidWorks Sustainability technology enables users to assess the environmental impact of their design to create more sustainable products.

CATIA

CATIA is the Company’s PLM solution for 3D collaborative creation. CATIA addresses the complete product development process, from early product concept specification through product in service. CATIA V6 is designed to enable the spectrum of next generation collaborative virtual design. Its product portfolio is consists of four main domains, which include systems, shape design, mechanical design and equipment engineering. CATIA Systems captures, manages, and tracks product requirements with traceability, ensuring that early requirements are met accurately all along the product development cycle. CATIA Shape provides a line of surfacing, reverse engineering, and visualization solutions to create, modify, and validate any type of complex shapes and help streamline the transition and collaboration among industrial designers. CATIA Mechanical delivers a collaborative and flexible design environment with concurrent engineering and change management through relational design. CATIA Equipment provides an integrated environment that enables the collaborative detailed design of electronic, electrical, and fluidic systems in context of a virtual product.

SIMULIA

SIMULIA provides a scalable portfolio of realistic simulation solutions designed to enable companies across a range of industries to improve product performance, reduce the number of physical prototypes and drive innovation. SIMULIA’s V6 portfolio spans include finite element analysis, multi-physics solutions, optimization analysis , and simulation lifecycle management. Its finite element an! alysis so! ftware companies are able to create and test virtual prototypes of products and processes. Its multi-physics solutions enable companies to reach beyond the boundaries of a single domain. SIMULIA also provides design exploration and optimization technology, enabling designers and engineers to perform rapid trade-off studies of real-world behavior and accelerate product development. SIMULIA offers simulation lifecycle management, based upon the Company’s ENOVIA architecture offering an open collaborative platform for management of simulation data, processes and intellectual property.

DELMIA

DELMIA covers the Company’s PLM digital manufacturing solutions ranging from virtual process definition, workcell set-up, optimization, scheduling, and operation, to maintenance of real-time production systems. DELMIA V6 covers four principal domains, including Manufacturing planning, with 3D process and resource planning tools for creating and optimizing build -to-order and lean production manufacturing systems; plant and resources engineering, with tools to virtually define and optimize manufacturing assets concurrently with manufacturing planning; program and control engineering, to virtually program, validate and simulate manufacturing systems for the virtual commissioning of production facilities, and control and production execution, which offers an accurate virtual production system to enable companies to track real time production activities, perform schedule changes, launch new programs and introduce model changeovers, and schedule maintenance operations.

ENOVIA

ENOVIA addresses business process needs across a broad spectrum of industries, managing simple, as well as engineered, complex products. The ENOVIA V6 products are organized by business processes, which include governance, global sourcing, global sourcing, and unified live collaboration. The Governance domain is designed to help companies launch enterprise new product introductions on time and on ! budget. G! overnance includes these sub-processes: Requirements Management, Portfolio Configuration, Program Management, Decision Support Business Intelligence, and Compliance. The Global Sourcing domain allows companies to leverage supply chain capabilities throughout the product lifecycle. The IP Lifecycle domain helps eliminate costly product development errors as it is designed to enable improved cross-functional product design, manufacturing planning and performance simulation. The Unified Live Collaboration domain allows companies to deploy product lifecycle processes across the extended enterprise by providing a single, real-time view of information protocol (IP) across all business process domains, collaborative process management capabilities, and a service-oriented architecture that integrates with other enterprise system

The Company competes with Parametric Technology Corporation, ANSYS, Inc., MSC Software Corporation, Oracle Corporation, SAP AG, Siemens PLM Sof tware, Adobe, Altair Engineering, Autonomy, Aveva, Bentley, Google, Intergraph, MathWorks, Nemetschek AG, Right Hemisphere, and Autodesk, Inc.

Advisors’ Opinion:

  • [By Rich Duprey]

    At the May 30 annual shareholders’ meeting of Dassault Systemes (NASDAQOTH: DASTY  ) , a dividend of 0.80 euros per share for fiscal 2012 was agreed upon, with each investor able to determine whether he or she wanted to receive the payout in cash or in new shares of the 3-D design software specialist.

Best Tech Companies To Own For 2014: Celgene Corp (CELG)

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company’s primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquir ed Avila Therapeutics.

The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufactur ing facility in Boudry, Switzerland.

Commercial! Stage Products

REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.

REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatm ent of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.

THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THA LOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.

ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin’s T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to N ovartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.

Preclinical and Clinical-Stage Pipeline

The product candidates in the Company’s pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.

The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).

The Company’s oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company’s new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis a nd a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.

At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company’s research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn’s disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.

The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to de velop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.

The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).

Advisors’ Opinion:

  • [By Ben Levisohn]

    It’s hard not to think it might be. Today, Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Celgene (CELG), Amgen (AMGN) and Vertex Pharmaceuticals (VRTX).

  • [By Ben Levisohn]

    Mylan (MYL) wants to start preparing a generic version of two Celegene (CELG) drugs. Celegene obviously wants to make that as difficult as possible. And now they’re heading to court.

  • [By Jake L’Ecuyer]

    Shares of Acceleron Pharma (NASDAQ: XLRN) got a boost, shooting up 16.74 percent to $39.54 after Form 8-K for Acceleron Pharma showed that Celgene (NASDAQ: CELG) will buy 1.1 million shares for $47.15 million.

Best Tech Companies To Own For 2014: Nortech Systems Incorporated(NSYS)

Nortech Systems Incorporated operates as a contract manufacturing company. It manufactures wire harness cable and printed circuit board assemblies, electronic sub-assemblies, higher level assemblies, and complete devices. The company also provides value added services and technical support, including design, testing, prototyping, and supply chain management; and repair services on circuit boards used in machines in the medical industry. In addition, it engages in the design, manufacture, and post-production service of electronic and electromechanical medical devices for diagnostic, analytical, and other life-science applications. Nortech Systems Incorporated serves various industries that include aerospace and defense; medical; and the industrial markets, which include industrial equipment, transportation, vision, agriculture, and oil and gas. The company markets its products through sales force and independent manufacturers? representatives. Nortech Systems Incorporated w as founded in 1981 and is headquartered in Wayzata, Minnesota.

Advisors’ Opinion:

  • [By James E. Brumley]

    In a perfect world stocks would move in predictable, manageable ways. We don’t live – nor do we trade in – a perfect world. In the real world we have to adapt to and deal with the curve balls the market throws us, and there are no two stocks that illustrate that point better than Document Security Systems, Inc. (NYSEMKT:DSS) and Nortech Systems Incorporated (NASDAQ:NSYS) to today. While both NSYS and DSS are up today, one’s overbought and ripe for a pullback, while the other is likely at the beginning of a trade-worthy rally.